The cells that have been used in clinical trials of cell-based therapies in PAD include bone marrow mononuclear cells bone marrow mesenchymal stem cells, granulocyte colony stimulating factor-mobilized peripheral blood mononuclear cells, endothelial progenitor cells, and granulocyte colony stimulating factor monotherapy [13]. Here, CSF3 is linked to peripheral arterial disease.